TrialNature communications2023

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.

Sun Min Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.